Abstract: Use of a CHV antigen for the preparation of a vaccine against canine herpesvirosis, which is intended to be administered to gestating bitches as close as possible to whelping, preferably during the final third of gestation, and which produces a high level of anti-CHV antibodies in gestating bitches at the time of whelping, inducing protection in the puppies by transfer of antibodies during suckling. Inactivated anti-CHV vaccine or subunit vaccines, which can be used for vaccinating gestating bitches to protect the puppies by transfer of antibodies.

Abstract: The present invention relates to a treatment for animals having canine distemper by administering a composition comprising an attenuated canine distemper virus a sub-vaccine virus level effective to alleviate symptoms canine distemper. The invention also provides a treatment for animals having canine distemper by administering a composition comprising an attenuated canine measles virus a sub-vaccine virus level effective to alleviate symptoms canine distemper.

Abstract: The present invention relates to a treatment for animals having canine distemper by administering a composition comprising an attenuated canine distemper virus a sub-vaccine virus level effective to alleviate symptoms canine distemper. The invention also provides a treatment for animals having canine distemper by administering a composition comprising an attenuated canine measles virus a sub-vaccine virus level effective to alleviate symptoms canine distemper.

Abstract: A method for preventing canine coronavirus in dogs is disclosed which comprises administering to a dog a live or inactivated vaccine prepared from transmissible gastroenteritis virus of swine (a TGEV vaccine). An inactivated vaccine composition for use in such a method and a process for the manufacture of the inactivated vaccine composition are described.

Abstract: The present invention is a method for the production of a subunit vaccine against canine parvovirus (CPV). The method includes the step wherein a recombinant protein VP2 of CPV is obtained by using the replication of a recombinant baculovirus wherein the gene corresponding to VP2 has been previously inserted in cells of a permissive host. The protein VP2 obtained has the capacity of forming empty VP2 capsids with high immunogenicity and can be provided as a vaccine formulation for protecting dogs against CPV infection the recombinant baculovirus AcMNPV.pCPVEx17 expresses the VP2 of CPV in conditions making possible the formulation of pseudo-viral capsids.

Abstract: This invention provides a vaccine which contains, per dose, an effective immunizing amount of an inactivated feline enteric coronavirus and a suitable carrier. The vaccine of this invention may also contain an adjuvant, an effective immunizing amount of a second inactivated virus and a an effective immunizing amount of an inactivated bacteria. Additionally provided by this invention is a method of immunizing a dog against disease caused by canine coronavirus involving administering to the dog a dose of the vaccine of this invention. The method of this invention may also involve administering one or more additional doses of vaccine to the dog, immunizing the dog against disease caused by a second virus and immunizing the dog against disease caused by a bacteria.

Abstract: A non-essential region in strains of live non-pathogenic immunogenic canine adenovirus is described. The insertion of genes from pathogenic carnivora viruses into this region, with suitable expression control systems, without prejudicing the stable reproducibility of the adenovirus vector is described. Such recombinant canine adenoviruses modified to contain a gene coding for an antigen or immunogenic agent, in association with an effective promoter for the gene, are described.

Abstract: Method for the production of a subunit vaccine against porcine parvovirus (PPV). The method is comprised of a first step wherein a recombinant protein VP2 of PPV is obtained by using the replication of a recombinant baculovirus wherein the gene corresponding to VP2 has been previously inserted in cells of a permissive host. The protein VP2 obtained in this invention has the capacity of forming empty chimeric capsids with high immunogenicity and can be provided as a vaccine formulation for protecting pigs against PPV infection. The recombinant baculovirus AcMNPV.pPPVEx8 expresses the VP2 of PPV in conditions making possible the formation of pseudo-viral capsids.

Abstract: A live or inactivated canine corona virus vaccine is provided which is derived from a virus of the novel antigenic type of the canine corona virus strain I-743 (CNCM, Institut Pasteur, Paris). A method for the preparation of this vaccine and the use of said vaccine in protecting susceptible animals against canine corona virus injection are also disclosed.